At ChemAlive, our goal is to allow the full and automatic calculation of accurate and reliable data for molecular properties and synthetic reactions available to all chemists from basic 2D chemical syntax. Our technologies beckon a future where, through computation, we know everything about a molecule and how to make it before the first test tube is in hand. A future where R&D is more directed, chemical processes are more efficient, more environmentally sound and the chemical industry is able to tackle more technological and medicinal challenges faster, for less, and with a greater beneficial impact and scope on society.

Meet the Team

with over 50 years experience in computational and experimental chemistry


Peter Jarowski, Ph. D.


Peter is an expert in the application of computational methods to molecular design. After NYU (B. Sc.), UCLA (Ph. D.), ETH, EPFL and as a former professor of chemistry, he has the vision to achieve reliable, meaningful chemical predictions without the hassle of the technical aspects of computational chemistry.

Laetitia Bomble

Laetita Bomble, Ph. D.


Laetitia is an expert at scientific programming for chemical analysis, especially the quantum dynamics of molecules. After Université de Paris-Sud (Ph. D.), and EPFL, Switzerland she integrates her knowledge of programming to bring new challenge-specific functionality to the chemistry community.


Thomas Eaton, Ph. D.

Co-founder/Business Developer

Thomas studied chemistry at Oxford University and obtained his Ph. D. from the University of Basel in organic chemistry. Following a career at Deloitte in management consulting  and UBS in contract negotiation he drives the team to bridge the gap between the science and the business case.


Stephanie Labouille, Ph. D.

Technical Sales Lead

Stéphanie is a computational chemist with extensive experience in reaction modelling and molecular dynamics. She obtained her Ph. D. from the Ecole Polytechnique, Palaiseau, and held postdoctoral positions at the University of Bristol, UK, and the Ecole Normale Supérieure, Paris. She is leading the technical sales team for ChemAlive.


Martin Ockajak, MSci

VP of Engineering

Martin is a software engineer with a Masters in computer science focused on distributed computing and artificial intelligence. He enjoys designing complex systems using cutting edge technology and leading teams to build deep technology products.


Alexandra Wahab, M.S.


Alexandra studied biochemistry at the University of Geneva before obtaining a master’s degree in Chemistry from the University of Basel, where she specialized in the atomistic simulation of biomolecules. Her main motivation is to improve computational tools to help research in the pharmaceutical and medical field.

Meet the Business Advisory Board

with expertise across Chemistry, Software Development & Business

Victor Canivell is an experienced executive with a successful track record as European director and VicePresident of a number of high tech multinationals (HP, 3Com, Silicon Graphics, PerkinElmer) and CEO/ Board Member of innovative software start-ups in the security, bioinformatics and SaaS markets. His current interests reside in quantum computing, security and AI. Victor holds a PhD in Physics from UB, an MBA from ESADE and an extensive international business experience having worked and lived in the UK, Germany, Switzerland, Spain and the US.

Willi Studer is the founder of Proviatus Ltd, a Consulting firm specialized in Change and
Transition Management, Executive Coaching and HR Development. He has a strong business
background with both project management expertise and people management experience.
Willi holds a Master of Law degree of the University of Zurich, and a Diploma in Organizational
Psychology from Insead, France (Consulting and Coaching for Change). He is of Swiss and French nationality who speaks fluent German, French, English, and Swiss German.

Jacques Bauer is an expert medicinal chemistry professional having directed R&D at Vifor Pharma for many years. He is helping ChemAlive gain access to key connections in CRO companies within Switzerland and refining our business positioning. He is a natural products chemist and biologist with more than 25 years of global experience in pharmaceutical industry at an international level in R&D, multi-project management, drug development in oncology and immunology, drug discovery to clinical level phase I, production development and a strong experience in intellectual property.

Meet the Scientific Advisory Board

with expertise across Quantum Chemistry, Software Development & Pharmaceuticals

Jiabo Li has very broad experience in scientific software development and scientific innovation, particularly in drug-like molecular modeling. His CAESAR algorithm for drug-like molecule conformation search has been widely used in compute-aided drug design. He is very passionate about developing highly efficient algorithms for high performance computing, especially in GPU accelerated molecular shape screening. His more recent interests are in artificial intelligence, including deep learning research, computer vision, natural language processing. He is also the main author of VB2000, a modern valence bond program which is open sourced to the scientific community. Jiabo holds a Ph.D. in Quantum Chemistry, and was Alexander von Humboldt Research Fellow during his two year stay in Germany. He is now working and living in New York.
Dr. Wade recently founded Informative Chemistry Solutions in 2020 to apply his over 25 years’ experience in cheminformatics and medicinal chemistry for difficult projects in Drug Discovery and related chemistry intensive fields. Previously at BioBlocks, Inc, Dr. Wade was the main inventor of the Leap-to-Lead platform that applied chemistry innovation, cheminformatics and next generation FBLD to lead discovery. He also spent 7 years at Neurocrine Biosciences as a Director of Medicinal Chemistry where he advanced two small molecule candidates for Investigational New Drug (IND) filings. One candidate, ORILISSA (elagolix) was approved for endometriosis in the US during 2018. Prior to this, Dr. Wade spent 8 years at Abbott where he was involved in developing the Company’s combinatorial chemistry informatics to parallel synthesis, solid phase synthesis and medicinal chemistry. Dr. Wade is an author of over 25 publications and a co-inventor on more than 20 issued US patents. He has a Ph.D. in Bioorganic Chemistry from the California Institute of Technology (Caltech) and a BA in Chemistry from Cornell University.